Peptide · Growth-hormone-releasing hormone (GHRH) analogue
CJC-1295
A modified analogue of growth-hormone-releasing hormone, developed pharmaceutically and never approved; often sold paired with ipamorelin.
No human authorisationSold for research. No regulator has authorised it for people.
- Legal status · US
- No human authorisation
- Evidence in people
- Molecule
- Growth-hormone-releasing hormone (GHRH) analogue
- In sport
- Prohibited (WADA)
- Status checked
Regulatory status · United States
This describes the position in the United States. Rules in Spain differ; an approved peptide medicine there is in its national register.
No marketing authorisation anywhere, and not on the 503A Bulks List. The FDA lists its compounding nomination as withdrawn.
Prohibited at all times under WADA class S2 (growth-hormone-releasing factors).
What changed, and when
Shown by the FDA among nominations withdrawn for 503A.
What to be careful about
The "CJC/ipamorelin" pairing is a vendor product, not a studied combination. Neither component is an authorised medicine.
Why there is no dosing information here
There is no authorised human dose to report. Any figure printed here would come from a vendor or a forum, and would look exactly like one taken from an approved label — which is the specific confusion that makes this category dangerous.
Sources
- FDA — bulk drug substances that may present significant safety risks (Category 2), page current as of 22 April 2026
- WADA Prohibited List
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.